• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Castle Biosciences Honored with Top Workplaces Awards

    7/11/24 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care
    Get the next $CSTL alert in real time by email

    Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards

    Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2024 Top Workplaces program, including: a third consecutive Arizona Top Workplaces award from AZ Central, the digital home of The Arizona Republic newspaper; a second consecutive national Healthcare Industry Top Workplaces award; and five Top Workplaces Culture Excellence Awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and Purpose & Values.

    "We are incredibly honored to have been named a Top Workplace in Arizona for the third year in a row in addition to being twice-recognized as a national Top Workplace in the Healthcare Industry among so many distinguished companies," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "Receiving multiple, consecutive Top Workplace designations holds immense significance, as they stem directly from feedback received from our Castle team members. These achievements exemplify our steadfast commitment to fostering an exceptional, people-first workplace culture that inspires our team members and fuels our shared passion for improving patient care."

    Now in its 17th year, the Top Workplaces program surveys and celebrates people-first organizations nationally and across 60 regional markets. Top Workplace designations are garnered solely through anonymous employee feedback gathered through a third-party survey administered by Energage. The confidential survey uniquely measures the employee experience and its component themes, including employees feeling "respected & supported," "enabled to grow" and "empowered to execute," among others. Additionally, it measures 15 culture drivers that are indicative of successful organizations, such as alignment, execution and connection.

    Earlier this year, Castle earned a national Top Workplaces award (also for the third consecutive year) and also received five Top Workplaces Culture Excellence Awards (multiple years running) for continued excellence in the following areas of its company culture:

    • Innovation (2022, 2023, 2024), for creating a culture where new ideas are encouraged, which helps employees reach their full potential and benefits performance.
    • Work-Life Flexibility (2023, 2024), for building a culture that enables employees to meet the demands of their personal lives while maintaining high performance.
    • Compensation & Benefits (2022, 2023, 2024), for providing packages employees believe are fair for the work being done and compared to others in the industry.
    • Leadership (2022, 2023, 2024), for organizational leaders who inspire confidence in employees and the company direction, listening to what matters most to employees and using that insight in decision making.
    • Purpose & Values (2022, 2023, 2024), for successfully communicating the company mission and integrating those aspirations into the culture.

    "Earning a Top Workplaces award is a badge of honor for companies, especially because it comes authentically from their employees," said Eric Rubino, Energage chief executive officer. "In today's market, leaders must ensure they're allowing employees to have a voice and be heard; that's paramount. Top Workplaces do this, and it pays dividends."

    About Castle Biosciences

    Castle Biosciences (NASDAQ:CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

    Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

    DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

    About Energage

    Making the world a better place to work together.™

    Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 18 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit energage.com or topworkplaces.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240711288149/en/

    Get the next $CSTL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CSTL

    DatePrice TargetRatingAnalyst
    12/14/2023$25.00Buy
    Guggenheim
    1/5/2023$54.00Sector Outperform
    Scotiabank
    1/7/2022$59.00Overweight
    Stephens & Co.
    11/9/2021$85.00 → $75.00Outperform
    SVB Leerink
    7/14/2021$80.00 → $85.00Outperform
    SVB Leerink
    More analyst ratings

    $CSTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres. & Chief Exec. Officer Maetzold Derek J sold $158,757 worth of shares (4,017 units at $39.52), decreasing direct ownership by 5% to 83,698 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    2/5/26 4:17:22 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Pres. & Chief Exec. Officer Maetzold Derek J sold $160,732 worth of shares (4,017 units at $40.01), decreasing direct ownership by 4% to 87,715 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    1/22/26 4:15:22 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Pres. & Chief Exec. Officer Maetzold Derek J was granted 62,219 shares, increasing direct ownership by 211% to 91,732 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    1/14/26 4:30:11 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Castle Biosciences Inc.

    SCHEDULE 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    1/21/26 1:21:12 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)

    1/13/26 9:43:02 AM ET
    $CSTL
    Medical Specialities
    Health Care

    SEC Form 144 filed by Castle Biosciences Inc.

    144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    1/5/26 5:09:12 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

    FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/483643109, or via the webcast link on the Investor Relations page of the Company's website: htt

    2/5/26 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

    2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Year-end 2025 cash, cash equivalents and marketable investment securities expected to be approximately $300 million FRIENDSWOOD, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2025. "We are extremely pleased with our excellent fourth quarter and ful

    1/11/26 4:00:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FRIENDSWOOD, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 15, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 83 employees covering an aggregate of 139,494 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting c

    12/19/25 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Castle Biosciences with a new price target

    Guggenheim initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $25.00

    12/14/23 6:54:55 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Scotiabank initiated coverage on Castle Biosciences with a new price target

    Scotiabank initiated coverage of Castle Biosciences with a rating of Sector Outperform and set a new price target of $54.00

    1/5/23 7:53:37 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Stephens & Co. initiated coverage on Castle Biosciences with a new price target

    Stephens & Co. initiated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $59.00

    1/7/22 5:42:05 AM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Leadership Updates

    Live Leadership Updates

    View All

    Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

    The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit

    4/30/24 4:30:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

    -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

    10/23/23 8:00:00 AM ET
    $CSTL
    $EQ
    $ICPT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors

    SAN DIEGO, May 26, 2021  /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful

    5/26/21 12:42:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Financials

    Live finance-specific insights

    View All

    Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

    FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/483643109, or via the webcast link on the Investor Relations page of the Company's website: htt

    2/5/26 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences Reports Third Quarter 2025 Results

    Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q3 2024 Raising full-year 2025 revenue guidance to $327-335 million from $310-320 million Announced launch of AdvanceAD-Tx™, the Company's test designed to guide systemic treatment decision making in patients ages 12 and older with moderate-to-severe atopic dermatitis (AD) Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that

    11/3/25 4:07:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

    FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2025, after the close of market on Monday, Nov. 3, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/153584002, or via the webcast link on the Investor Relations page of the Company's website:

    10/13/25 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    11/14/24 4:40:39 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    11/13/24 6:44:33 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    7/8/24 4:32:39 PM ET
    $CSTL
    Medical Specialities
    Health Care